"Designing Growth Strategies is in our DNA"

U.S. Heparin Market Size, Share, Analysis, By Product (Unfractionated Heparin (UFH) and Low Molecular Weight Heparin (LMWH)), By Source (Bovine and Porcine), By Application (Deep Vein Thrombosis & Pulmonary Embolism, Atrial Fibrillation, Heart Attacks, Stroke, and Others), By Route of Administration (Intravenous Infusion and Subcutaneous Injection), and By End-user (Hospitals & ASCs, Clinics, and Others), and Country Forecast, 2024-2032

Last Updated: December 08, 2025 | Format: PDF | Report ID: FBI108746

 


To get information on various segments, share your queries with us

ATTRIBUTE

DETAILS

Study Period

2019-2032

Base Year

2023

Estimated Year

2024

Forecast Period

2024-2032

Historical Period

2019-2022

Growth Rate

CAGR of 4.7% from 2024 to 2032

Unit

Value (USD Billion)

Segmentation

By Product

  • Unfractionated Heparin (UFH)
  • Low Molecular Weight Heparin (LMWH)

By Source

  • Bovine
  • Porcine

By Application

  • Deep Vein Thrombosis & Pulmonary Embolism
  • Atrial Fibrillation
  • Heart Attacks
  • Stroke
  • Others

By Route of Administration

  • Intravenous Infusion
  • Subcutaneous Injection

By End-user

  • Hospitals & ASCs
  • Clinics
  • Others
  • 2019-2032
  • 2023
  • 2019-2022
  • 90
Download Free Sample

    man icon
    Mail icon
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann